Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fursultiamine
Therapeutic Area: Ophthalmology Product Name: Alinamin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Blackstone Life Sciences
Deal Size: $2,277.2 million Upfront Cash: Undisclosed
Deal Type: Divestment August 24, 2020
Details:
The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxymetazoline
Therapeutic Area: Ophthalmology Product Name: Upneeq
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: RVL Pharmaceuticals
Deal Size: $89.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement July 28, 2020
Details:
Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Brimonidine Tartrate,Brinzolamide
Therapeutic Area: Ophthalmology Product Name: Ailamide
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
